FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
about
Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acidThe functional significance of microRNA-145 in prostate cancerThe many roles of histone deacetylases in development and physiology: implications for disease and therapyMacrocyclic histone deacetylase inhibitorsEpigenetic control of skull morphogenesis by histone deacetylase 8Epigenetic therapy in gastrointestinal cancer: the right combinationClinical use and applications of histone deacetylase inhibitors in multiple myelomaHDAC and HDAC Inhibitor: From Cancer to Cardiovascular DiseasesEpigenetic treatment of solid tumours: a review of clinical trialsMolecular Targeted Therapies of Aggressive Thyroid CancerCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaTargeting JAK2 in the therapy of myeloproliferative neoplasmsHistone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and preventionThe delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiologyMitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse modelsStructural Basis of the Antiproliferative Activity of Largazole, a Depsipeptide Inhibitor of the Histone DeacetylasesMetalloprotein–Inhibitor Binding: Human Carbonic Anhydrase II as a Model for Probing Metal–Ligand Interactions in a Metalloprotein Active SiteSynthesis, Structure, and Antibiotic Activity of Aryl-Substituted LpxC InhibitorsEpigenetic modulators as therapeutic targets in prostate cancerOngoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory AgentsAdvancements in the delivery of epigenetic drugsA KRAS-directed transcriptional silencing pathway that mediates the CpG island methylator phenotypeTwo new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse modelBryostatin modulates latent HIV-1 infection via PKC and AMPK signaling but inhibits acute infection in a receptor independent mannerA novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancerVorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanismsProstatic cell-specific regulation of the synthesis of MUC1-associated sialyl Lewis aFrom bench to bedside: lessons learned in translating preclinical studies in cancer drug developmentInhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphomaVorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cellsThe case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discoveryEvolving Therapies and FAK Inhibitors for the Treatment of CancerSynthesis and antiproliferative activity of hydroxyferrocifen hybrids against triple-negative breast cancer cells.Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumorsPhase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumorsGamma-delta t-cell lymphomas.
P2860
Q24596282-26D292A2-C2F9-469F-B80A-EE2EBC1C11D7Q24606503-257AB87D-8B0D-46BD-8D9D-1E2B4B7A9A9EQ24628821-38A86B5A-F1FA-4744-9878-DE739B43FF22Q24629065-14890B2F-8197-45C0-AED5-6431D8E1055EQ24646214-627BB1DD-AC55-4DA1-8FE7-48C975129135Q26745709-CBCAA425-B084-49B6-B8D3-39DE28D55D50Q26745930-AC39A76B-5491-4BAB-B06E-563465A35092Q26766640-FD4932A6-65A4-4CA8-9FBC-9D26AF161438Q26773803-5893BE5B-80B9-4947-AE08-F976E0022A55Q26774734-674AF834-6D36-419C-B190-11A0AE9D364FQ26851166-8C89BE30-1010-4BB0-83BD-1322F15CA7A8Q26860796-1168C6A0-BF8F-4092-9B4B-2F1943D82627Q26994739-EA582EBC-AABA-4814-BD6A-3C403B4FA4BFQ27015793-FF767750-1585-43BB-8895-FBD823799BB6Q27310013-DF064C4A-FF4D-4836-B8F8-594AD76E41EBQ27671010-898DAA5F-899E-46BB-95AA-6E4C0AB058BEQ27678293-166FAA09-F5FB-47F9-BD38-C56850C98314Q27679369-B2803013-5D26-4EFF-AA8A-C9014697FB16Q28071912-8B09F7E4-E2D8-4A83-93AF-7D829CCADB8FQ28079455-CA678637-0762-4F46-ADBA-DE44E25B55EAQ28088478-EA341865-5630-4439-A3BF-F4B11D3AF873Q28117127-6E896AA6-33B4-4D7B-9EDD-5AC660D1D5ACQ28472583-0A3E3E40-229E-412F-9F5F-7E8D37E3E329Q28474468-3C309D67-739B-4D2E-8DFD-55B8DCAC13EFQ28475503-BBCB9E39-FDFB-4CC1-8176-DAC25F0EF0FEQ28484904-690D3326-7ECA-44AA-A4F0-CCA972E74BB3Q28486623-ECDF715C-C59D-4814-A3BE-C5B5B19CE176Q28533949-D3204DB1-28D6-4291-98C7-7939308AA4F9Q28534761-133DF843-79CC-464C-A16F-5C3FC4201B07Q28743758-8494C814-3831-407B-8A41-3471DB751EF4Q28751328-A546580D-1173-4F76-969C-731F4553F683Q28972291-D8F08CBC-376E-4739-8F2E-ECC0D049EA0CQ30683354-8356E97A-D5ED-4CE8-A9CF-A08C4DBA1904Q33393266-EE360841-2FCB-4C8F-A0A4-95382AEAD5ACQ33399121-1B123B09-6F8C-487D-B4F3-1BD35611B243Q33405714-028A80F6-57F1-468F-8514-81A27B6342EFQ33408000-9E2F5B0A-4361-4B7B-B6DC-8B35A125539AQ33410544-09110F58-79B7-4DCD-830C-753DE5267186Q33412724-7BB9206C-295E-4BE7-A4E8-006BE62AED5EQ33417290-F269408B-19AD-4A23-BECE-9C4EA9DEE960
P2860
FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
FDA approval summary: vorinost ...... ary cutaneous T-cell lymphoma.
@ast
FDA approval summary: vorinost ...... ary cutaneous T-cell lymphoma.
@en
type
label
FDA approval summary: vorinost ...... ary cutaneous T-cell lymphoma.
@ast
FDA approval summary: vorinost ...... ary cutaneous T-cell lymphoma.
@en
prefLabel
FDA approval summary: vorinost ...... ary cutaneous T-cell lymphoma.
@ast
FDA approval summary: vorinost ...... ary cutaneous T-cell lymphoma.
@en
P2093
P1433
P1476
FDA approval summary: vorinost ...... ary cutaneous T-cell lymphoma.
@en
P2093
Bhupinder S Mann
John R Johnson
Martin H Cohen
Richard Pazdur
Robert Justice
P304
P356
10.1634/THEONCOLOGIST.12-10-1247
P577
2007-10-01T00:00:00Z